IMV (TSE:IMV) Shares Down 1.8% – What’s Next?

IMV Inc. (TSE:IMV) fell 1.8% on Monday . The company traded as low as C$1.07 and last traded at C$1.12. 15,761 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 56,822 shares. The stock had previously closed at C$1.14.

IMV Stock Performance

The company has a debt-to-equity ratio of 1,231.01, a current ratio of 2.93 and a quick ratio of 2.32. The firm has a market capitalization of C$13.12 million, a P/E ratio of -0.18 and a beta of 1.52. The stock’s fifty day moving average price is C$1.12.

IMV Company Profile

IMV Inc operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.